Dabigatran etexilate mesylate
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:anticoagulant |
| gptkbp:activeIngredient |
gptkb:dabigatran
|
| gptkbp:antidote |
gptkb:idarucizumab
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B01AE07
|
| gptkbp:CASNumber |
211915-06-9
|
| gptkbp:chemicalFormula |
C34H41N7O5·CH4O3S
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:developedBy |
gptkb:Boehringer_Ingelheim
|
| gptkbp:eliminationHalfLife |
12-17 hours
|
| gptkbp:excretion |
gptkb:kidney
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dabigatran etexilate mesylate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Pradaxa
|
| gptkbp:mechanismOfAction |
direct thrombin inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
723.85 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
bleeding
gastrointestinal upset |
| gptkbp:usedFor |
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis treatment of pulmonary embolism |
| gptkbp:bfsParent |
gptkb:DB08890
|
| gptkbp:bfsLayer |
7
|